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The double-edged role of copper in the fate of
amyloid beta in the presence of anti-oxidants†
Jing Yang,‡ab Xueli Zhang,‡ac Yiying Zhu,d Emily Lenczowski,e Yanli Tian,af Jian Yang,ac
Can Zhang,g Markus Hardt,d Chunhua Qiao,b Rudolph E. Tanzi,g Anna Moore,a
Hui Ye*e and Chongzhao Ran *a
The biological fate of amyloid beta (Ab) species is a fundamental question in Alzheimer’s disease (AD)
pathogenesis. The competition between clearance and aggregation of Abs is critical for the onset of AD.
Copper has been widely considered to be an inducer of harmful crosslinking of Abs, and an important
triggering factor for the onset of AD. In this report, however, we present data to show that copper can
also be an inducer of Ab degradation in the presence of a large excess of well-known intrinsic (such as
dopamine) or extrinsic (such as vitamin C) anti-oxidants. The degraded fragments were identiﬁed using
SDS-Page gels, and validated via nanoLC-MS/MS. A tentative mechanism for the degradation was
proposed and validated with model peptides. In addition, we performed electrophysiological analysis to
investigate the synaptic functions in brain slices, and found that in the presence of a signiﬁcant excess of
vitamin C, Cu(II) could prevent an Ab-induced deﬁcit in synaptic transmission in the hippocampus.
Collectively, our evidence strongly indicated that a proper combination of copper and anti-oxidants
might have a positive eﬀect on the prevention of AD. This double-edged function of copper in AD has
been largely overlooked in the past. We believe that our report is very important for fully understanding
the function of copper in AD pathology.
Introduction
To date, drug development for Alzheimer’s disease (AD) has
been largely unsuccessful.1–6 However, emerging evidence
suggests that alternative approaches, such as adapting to
a healthy lifestyle, can signicantly improve or maintain
cognitive function in at-risk elderly people.7–10 Lifestyle adap-
tation, including a healthy diet, regular physical exercise and
cognitive training, can lead to a signicant increase in
production of intrinsic anti-oxidants such as dopamine and an
increase of the uptake of extrinsic anti-oxidants such as vitamin
C (Vc). In this report, we provide unexpected in vitro evidence
that a signicant excess of anti-oxidants such as Vc and dopa-
mine can facilitate copper-induced degradation of Abs. Our
results may be relevant to the benecial eﬀects of a healthy
lifestyle on AD prevention and treatment.
Originally, Cu(II) ion’s eﬀects on Ab have been considered to be
the cause of the harmful cross-linking of Abs, which signicantly
contributes to the development of Alzheimer’s disease.11–14
However, we recently accidentally discovered that Cu(II) could also
induce Ab degradation in the presence of extrinsic anti-oxidants
such as Vc and endogenous anti-oxidants such as dopamine. It
is believed that the cross-linking of Ab induced by Cu(II) originates
from an oxidative reaction with Abs. Atwood et al. reported that
Cu(II) could coordinate with Histidine 6, 13, and 14 (H6, 13, and
14) of Ab peptides, and could be further reduced by Vc to initialize
the oxidative cross-linking of tyrosine (Y10) of Abs.15 Cross-linking
and degradation of the proteins are the two primary outcomes of
an oxidative reaction of proteins/peptides.16–25 In the case of Ab,
the cross-linking of Ab by oxidative reactions has been well
recognized,11,12,26,27 however oxidative degradation of Ab, to the
best our knowledge, has not been intensively investigated and has
been overlooked in the past decades.
In the course of our investigation, we used a uorescent dye-
conjugated Ab (FAM-Ab42) for preparation of the cross-linking
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products with Cu(II) and Vc. Unexpectedly, two fast migrating
bands were detected on the SDS-PAGE gels. Their molecular
weights were less than 4KD, indicating that they were degraded
fragments of Abs. To investigate the oxidative degradation of
Abs, we rst used nanoLC-MS/MS to identify the degraded
fragments from native Ab42 and FAM-Ab42, and then we
proposed a possible degradation mechanism. To further eluci-
date the mechanism, a peptide fragment was used to mimic the
degradation reactions. Following these studies, we used FAM-
Ab42 as a model peptide to examine the eﬀects of diﬀerent
metal ions including Fe(III), Fe(II), Cu(II) and Zn(II), diﬀerent
reductants including well-known extrinsic compounds such as
Vc, curcumin, resveratrol and vitamin E (Ve), and intrinsic
compounds such as norepinephrine (NE) and dopamine
(DOPA) on the degradation of Ab. Moreover, we showed that the
combination of an anti-oxidant and an anti-aggregating drug
could slightly increase the fraction of the degradation products.
We also investigated whether the combination of Cu(II) and
anti-oxidants could provide neuronal protection benets.
Remarkably, eld excitatory postsynaptic potential (fEPSP)
recording on mouse brain slices indicated that the combination
of Cu(II) and a signicant excess of Vc could prevent synaptic
impairment induced by Abs.
Results
1. Discovery of the degradation of FAM-Ab42 by Cu(II) and Vc
The combination of Cu(II) and Vc has been used to investigate
the crosslinking of Ab.15 In the course of screening crosslinking
inhibitors, we incubated FAM-Ab42 with copper sulfate and Vc
for 24 hours, and the mixture was then subjected to SDS-PAGE
gel electrophoresis. Since FAM is a uorescent dye, we imaged
the gel directly on an imaging system. Surprisingly, we observed
two uorescent bands (bands A and B in Fig. 1a) that migrated
faster than the monomeric bands on the gel, suggesting that
their molecular weights are less than 4KD, and thus also
strongly suggesting that they represent degraded segments of
FAM-Ab42 (Fig. 1a). Control experiments with Cu(II) only were
conducted, and no degradation products were observed
(Fig. 1a). Opazo et al. reported the production of H2O2 upon
Cu(II) binding to Ab in the presence of Vc.28 To examine whether
H2O2 could induce degradation, we incubated FAM-Ab42 with
diﬀerent concentrations of H2O2. No apparent cleavage could be
detected, indicating that copper was necessary for the cleavage
(Fig. 1a).
2. Degradation of native human Ab42
To investigate whether Cu(II) could induce degradation of native
Ab42 in the presence of anti-oxidants, we incubated Ab42 with
CuSO4 and Vc (Ab42/Cu(II)/Vc ¼ 1 : 1 : 10) for 24 hours. Since
native Ab42 itself doesn’t have a direct uorescence readout like
FAM-Ab42, we attempted to visualize the possible degradation
products by western blotting. We observed that the density of
the monomeric band from the Cu(II)/Vc group was lower than
that from the control group, indicating that both crosslinking
and degradation were possible (Fig. 1b). Unfortunately, we
failed to visualize any bands faster than the 4KD band with Ab
antibody 6E10, whose specic epitope is Ab1–16 (Fig. 1b).
Similarly, Ab antibody 2H4, whose epitope is Ab1–8, also failed
to detect the lower molecular weight bands (data not shown).
These failures are likely due to the incapability of the antibodies
to recognize the degraded fragments. We veried this specula-
tion by western blotting with standard Ab6 and Ab12 peptides.
No apparent bands were observed with the antibodies (Fig. 1b),
conrming that western blotting was not suitable for quanti-
cation of the degradation of the native Abs.
3. Identication of the degraded fragments of native Ab42
by nanoLC-MS/MS
To further investigate the observed degradation, we used
nanoLC-MS/MS to detect the fragments of Ab42. In these
experiments we used Ab42 only as the control, and Ab42/Cu(II)/
Vc as the experimental group. It is well-known that during the
degradation of a peptide, H2O from the incubation medium
participates in the cleavage of the C–N bond via incorporating
a hydroxyl (OH) into the nal carboxylic acid product. In pro-
teomics studies, stable isotope labeling has been widely used to
introduce signature mass tags to accurately assign fragments of
proteins and peptides.29–31 To unambiguously identify the
fragments of Ab42, we took advantage of the stable isotope
labeling mass spectrometry method. To this end, we incubated
Ab42, CuSO4 and Vc in PBS buﬀer with 50% and 100% heavy
water (H2
18O) respectively to obtain 18O labeled degradation
products. Our analysis was based on the extracted ion current
ratio (XICR) of 18O/16O (heavy/light) of the sequence of interest.
To validate the degraded fragments, we rst compared the
XICRs of the control and treated groups in the PBS buﬀer with
50% H2
18O, and plotted a graph by normalizing to the XICR of
the control (R50% ¼ XICRCu/XICRControl) (Fig. 2a, black bars). In
principle, the higher the value a sequence has, the higher the
probability is that the sequence has 18O incorporated, and thus
Fig. 1 Degradation of Ab induced by Cu(II) and Vc. (a) SDS-PAGE of FAM-Ab42 with H2O2, Cu(II), and Cu(II)/Vc (1 : 10). Two fast migrating bands A
and B can be clearly seen. (b) Western blotting with 6E10 antibody for Ab42, Ab42/Cu(II)/Vc (1 : 10), Ab6 and Ab12. Ab6 and Ab12 cannot be
visualized with the antibody.
6156 | Chem. Sci., 2017, 8, 6155–6164 This journal is © The Royal Society of Chemistry 2017
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the sequence is more likely to be a cleavage product. From this
graph, we identied 60 sequences with R50% > 1, which corre-
sponded to the likely degraded fragments (ESI Table 1†). To
further validate the candidate sequences, we calculated R100%
(R100% ¼ EICRCu/EICRControl) for the sequences obtained from
the 100% H2
18O buﬀer (Fig. 2a, red bars). It is reasonable to
assume that, if the sequence is a degraded fragment, R100%
should be larger than R50% (R100% > R50%). With this additional
criterion, ten sequences were identied as the degraded
fragments (Fig. 2a le and right inserts). To conrm the reli-
ability of our analysis, we analyzed the R100% and R50% values of
the full Ab42 sequence, which was not totally degraded in the
analyzed solution. As expected, the R100% and R50% values of
Ab42 were very similar (Fig. 2a middle insert), indicating that
our analysis was reliable.
The nano-LC, MS, and MS/MS spectra of a representative
fragment, DAEFRH, are shown in Fig. 2b and c. Clearly, the MS
patterns of 0%, 50%, and 100% H2
18O buﬀer were shied, and
Fig. 2 Identiﬁcation of the degraded fragments of native Ab42 using nanoLC-MS/MS. (a) Relative intensities of the sequences of interest in 50%
(R50%, black bars) and 100% (R100%, red bars) of H2
18O buﬀer. The calculation was based on XICR (R50% or R100%¼ XICRCu/XICRControl). Left insert:
zoomed in image of the red circle; middle insert: XICR of the whole sequence of native Ab42; right insert: zoomed in image of the black circle. (b)
Skyline of nano-LC (left panel, red: normal MS; blue: 18O incorporated) and MS (right panel: purple) of a representative degraded fragment, Ab6
(DAEFRH), in 0% (control), 50% and 100% H2
18O buﬀer. Note that the MS patterns changed with the increasing H2
18O content. (c) MS/MS of the
representative degraded fragment Ab6 in (b).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6155–6164 | 6157
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are consistent with the expectation. The tandemMS/MS pattern
also ambiguously identied the sequence of the DAEFRH frag-
ment (Fig. 2c). The nano-LC, MS, and MS/MS spectra of the rest
of the fragments are listed in the ESI section (Fig. 1†).
Interestingly, all of the cleaved sites are adjacent to histi-
dines (H6, H13 and H14), whose imidazoles can coordinate with
Cu(II), indicating that the specicity of the degradation was
related to histidine. Histidine-specic oxidative degradation of
proteins/peptides in the presence of metal ions has been re-
ported,32 and our results are consistent with the reported
reference.
In addition, it has been reported that copper could oxidize
histidine to generate imidazolone;33–35 therefore it is necessary
to investigate whether fragments containing imidazolone can
be validated. Using the same criteria for identifying the non-
oxidized fragment, we conrmed that oxidized fragments of
Ab42 could be identied from the collection of nanoLC-MS/MS
data sets from 50% and 100% heavy water incubation. The
nano-LC, MS, andMS/MS of the oxidized fragments are listed in
ESI Fig. 1.†
4. Identication of the FAM-Ab42 fragments
To investigate the origin of the peptide fragments of the two fast
migrating bands A and B in Fig. 1a, we used the same protocol
as that of nanoLC-MS/MS for native Ab42. FAM-Ab6 was rst
identied (ESI Fig. 2†). For further conrmation, standard FAM-
Ab6 was used for electrophoresis, and the same mobility was
conrmed for this fragment as for the fastest migrating band B
(ESI Fig. 3a†). Initially, we speculated that FAM-Ab12 was the
fast-migrating band A; however, the mobility of the standard
FAM-Ab12 was not the same as band A (ESI Fig. 3a†). Our data
from the native Ab42 suggested that oxidized fragments were
possible. To conrm this we incubated standard FAM-Ab12 with
CuSO4 and Vc, and found that the mobility of the new band was
consistent with band A, indicating that band A was the oxidized
FAM-Ab12 (ESI Fig. 3b†).
5. Comparison of the native gel and SDS-gel for Abs
To investigate whether the cleavage behaviors of Abs are
diﬀerent between the native gel and SDS-gel, we performed an
electrophoresis experiment with SDS-gel and native gel for FAM-
Ab42. We found no apparent cleavage diﬀerence between the
two gel images. Similar to the results with the SDS-gel, two fast
moving bands (cleaved fragments) could be clearly seen from
the native gel imaging (ESI Fig. 3c†). We also investigated the
aggregation behavior of Abs with these two types of gel. We did
not observe signals from the aggregated Abs (high molecular
weight > 20 kD) with FAM-Ab42 from both gels (ESI Fig. 3c†),
which is likely due to the high degree of aggregation that could
quench the uorescence signal (high local concentration of
FAM). However, we also noticed some diﬀerences between the
two gels. Two low MW bands of oligomers could be clearly
observed with the SDS-gel, but not with the native gel. It is not
clear what caused this diﬀerence. To avoid the possible
quenching eﬀect of FAM dye, we performed western blotting for
FAM-Ab42 with both the SDS-gel and native gel, and found that
aggregation did occur (ESI Fig. 3d†). This result is consistent
with previous reports.11–15,36 In addition, we conducted western
blotting for the native Ab42, and images from both gels showed
that Cu(II)/Vc did induce aggregation of the native Abs (ESI
Fig. 3e†). This is similar to the result from FAM-Ab42. Taken
together, our data indicated that Cu(II)/Vc could induce both
cleavage and aggregation of Abs. However, in this report, our
focus was the cleavage of Abs, not the aggregation of Abs.
6. Eﬀect of oxygen on the cleavage of Ab peptides
To investigate whether oxygen is crucial for the cleavage, we
performed reactions of FAM-Ab42 with Cu(II) under both
aerobic and anaerobic conditions with and without anti-
oxidants. Anaerobic experiments were performed in an O2-free
glove-box, and all the solutions were prepared anaerobically by
purging with high purity nitrogen gas. As shown in ESI Fig. 4a
and b,† the degradation of Abs under anaerobic conditions was
signicantly decreased compared to the aerobic conditions,
suggesting that oxygen is essential for degradation induced by
Cu(II)/Vc. However, it is diﬃcult to have a completely air-free
environment for our experiments, and this could provide an
explanation for some cleavage that could still be observed under
the anaerobic conditions. For the cleavage induced by Cu(II)/
H2O2, our data suggested that oxygen was not essential (ESI
Fig. 4a and b†).
7. Mechanism studies for the cleavage of Ab peptides
To investigate the possible mechanism of the copper induced
cleavage, we rst used a short Ab fragment, YEVHH, as a model
peptide, in which Cu(II) can coordinate with the imidazoles of
the two histidines. The fate of the peptide in the presence of
CuSO4 and Vc was monitored by LC-MS to investigate: (1)
whether the model peptide can be cleaved; (2) if cleaved, what
were the products; (3) how the concentrations of the starting
peptide and newly generated fragments change at diﬀerent time
points. We found that YEVHH could be cleaved by Cu(II)/Vc,
resulting in total degradation aer 24 hours incubation (ESI
Fig. 5a†). At 3.5 hours incubation, we found twomajor products,
one being YEVHH + 16 Da, corresponding to the oxidized
product, and another being YEV, corresponding to the cleaved
product. Meanwhile, a dramatic decreasing of the intensity of
YEVHH + 16 Da was observed during the period of incubation of
3.5 hours to 24 hours. Nonetheless, the intensity of YEV was
signicantly increased (ESI Fig. 5a†), indicating that YEVVHH +
16 Da was the intermediate for the cleavage.
Based on the above results, we proposed a tentative mecha-
nism to explain the cleavage (ESI Fig. 5b†). Several reports37–42
have indicated that Cu(II) could coordinate with three imidaz-
oles from the Ab peptide (H6, H13 and H14) (ESI Fig. 5b†). In
the presence of Vc, the Cu(II) complex could be reduced to
a Cu(I) complex, which is ready to accept dioxygen (O2) to form
a Cu(I)–O2 complex.42–47 According to previous references, the
Cu(I)–O2 complex could undergo several steps to produce reac-
tive HOc (ESI Fig. 5b†), which could attach to the nearby imid-
azole to provide an imidazolone (also called 2-oxo-imidazole)
intermediate. Our data from the mimic experiments and
6158 | Chem. Sci., 2017, 8, 6155–6164 This journal is © The Royal Society of Chemistry 2017
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reports35,48–50 supported the existence of imidazolone (ESI
Fig. 5a†). Based on the reported mechanism for the oxidative
cleavage of peptides,16,50 HOc could also further attack the a-
position of the nearby amide bond to generate a free radical
intermediate, in which the amide bond will be cleaved with the
assistance of H2O (ESI Fig. 5b†).
8. Copper/Vc ratio for degradation
To investigate the eﬃciency of the cleavage with the combina-
tion of Cu(II) and Vc, we incubated FAM-Ab42 with diﬀerent
ratios of Cu(II)/Vc varying from 1 : 1 to 1 : 20. The results indi-
cated that the ratio was critical for eﬃcient degradation, with
a high Vc ratio promoting more eﬃcient cleavage. This strongly
suggests that the ratio of Cu(II) and Vc is the key for determining
the fate of Ab peptides (Fig. 3a and b). For quantication, we
used the total ROI signal from bands A and B, and normalized
the values to total ROI signals from the same positions of bands
A and B in the control FAM-Ab42 lane. Interestingly, we also
noticed that a low ratio/concentration of Cu(II) could not
signicantly induce the cleavage of Abs (ESI Fig. 6a†), which is
likely due to the requirement of coordination between Cu(II)
and the Ab peptide.
9. The degradation eﬀect of Zinc(II), Fe(III) and Fe(II)
It is well-known that Zn(II) and Fe(III)/Fe(II) play important roles
in triggering AD.51 Over-accumulation of these metal ions has
been found around the senile plaques. To test whether these
metal ions could also lead to degradation of Ab, we conducted
experiments with Zn(II), Fe(III), Zn(II) + Vc, and Fe(III) + Vc. No
obvious degraded products were observed with Zn(II) or Zn(II) +
Vc, probably due to the incapability of zinc(II) to induce oxida-
tion under this condition (Fig. 3c). Although it was reported that
Fe(III) could induce protein/peptide cleavage,23 no FAM-Ab42
degraded products were detected with either Fe(III) or Fe(III) + Vc
(Fig. 3c). In addition, there was no apparent degraded fragment
when FAM-Ab42 was incubated with Fe(II) with and without Vc
under both aerobic and anaerobic conditions (ESI Fig. 6b†).
This data may indicate that the degradation of FAM-Ab is Cu(II)
specic.
10. Degradation of Abs with other well-known anti-oxidants
To investigate whether other well-known anti-oxidants are
capable of promoting the degradation of FAM-Ab42, we tested
extrinsic vitamin E (Ve), curcumin, resveratrol, endogenous
dopamine and norepinephrine as reducing reagents. We found
that all of these anti-oxidants could lead to the degradation of
FAM-Ab42 in the presence of Cu(II) (Fig. 3d and e). Remarkably,
the intrinsic anti-oxidants dopamine and norepinephrine are
tightly related to neuron activity, with dopamine being one of
the important molecules released from synapse activation. A
low dopamine level has been linked to AD.52 In addition, we also
compared the eﬀect of curcumin to its analogue CRANAD-5,
which doesn’t contain a phenolic group as a reducing
compound53 (ESI Fig. 7†). No degradation products were
detected with CRANAD-5, indicating that the cleavage induced
by curcumin originated from the oxidative reaction.
11. A combination of anti-oxidant and anti-aggregating
drugs increases the degree of degradation
The above results clearly indicate that Cu(II) plays a double-
edged sword role in the fate of Ab peptides. In principle,
aggregation and degradation are two competitive paths.
Therefore, in the presence of a compound that can reduce the
aggregation of Abs, the chance of Abs to undergo Cu(II)-induced
degradation would increase. To investigate this hypothesis, we
selected clioquinol (CQ), which is an antifungal and anti-
protozoal drug, and also has been clinically tested for AD.
Reportedly, CQ can reduce the aggregation of Abs in vitro and
signicantly lower the loading of Ab plaques in transgenic
Fig. 3 (a) SDS-PAGE of FAM-Ab42 with diﬀerent ratios of Cu(II)/Vc
(1 : 1, 1 : 5, 1 : 10 and 1 : 20). (b) Quantitative analysis of the cleaved
bands for each condition in (a) (n¼ 3). (c) SDS-PAGE of FAM-Ab42with
Cu(II)/Vc, Zn(II), Fe(III), Zn(II)/Vc, and Fe(III)/Vc. (d) SDS-PAGE of FAM-
Ab42 with CuSO4 and diﬀerent anti-oxidants, including Vc, vitamin E
(Ve), curcumin, NE, dopamine, and resrevatrol. FAM-Ab42 (Lane 1);
FAM-Ab42/Cu(II) 1 : 1 (Lane 2); FAM-Ab42/Cu(II)/anti-oxidants 1 : 1 : 20
(Lanes 3–8). (e) Quantitative analysis of the cleaved bands for each
condition in (d) (n¼ 3). (f) Quantitative analysis of the cleaved bands for
each condition in (g) (n ¼ 3). (g) SDS-PAGE of FAM-Ab42 with the
combination of Cu(II)/Vc and anti-aggregating drug clioquninol (CQ).
FAM-Ab42 (Lane 1); FAM-Ab42/Cu(II)/Vc 1 : 1 : 20 (Lane 2); Lanes 3–8:
FAM-Ab42/Cu(II)/Vc/CQ ¼ 1 : 1 : 20 : 0.1 (Ln3), 0.5 (Ln4), 1.0 (Ln5), 2.0
(Ln6), 5.0 (Ln7), 10.0 (Ln8).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6155–6164 | 6159
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mice.54,55 We tested the combination of CQ/Cu(II)/Vc with
various concentrations of CQ (the molar ratio of CQ/Cu(II): 0.1–
10).
Indeed, we found that low concentrations of CQ could
promote the degradation of FAM-Ab42 (Fig. 3f and g). However,
high concentrations of CQ prevent the degradation, probably
due to the coordination of CQ with Cu(II). We also tested scyllo-
inositol (AZD-103), a natural plant sugar currently in clinical
trials for AD therapy, as the anti-aggregating compound.56,57
However, no signicant increase in the degradation was
observed (data not shown).
12. Degradation of insoluble Ab40 aggregates and oligomers
To investigate whether the combination of Cu(II)/Vc can degrade
the aggregated Abs, we incubated Ab40 aggregates with CuSO4
and Vc for 72 hours. TEM images show that the aggregates/
brils could be degraded forming much shorter brils (Fig. 4a
and c). The debris from degraded brils can be clearly seen in
Fig. 4c. When the incubated solutions were tested with thio-
avin T, we observed a signicant decrease of uorescence
response in the presence of CuSO4 and Vc (Fig. 4b). A control
experiment showed that CuSO4 had no signicant eﬀect on the
uorescence of ThioT. These results suggested that the aggre-
gated Abs could be degraded by the combination of Cu(II) and
Vc.
Mounting evidence suggests that Ab oligomers are more
toxic than insoluble Abs.58–61 To investigate whether the Ab
oligomers could be degraded by Cu(II)/Vc, we rst used TEM to
characterize the Ab oligomers. TEM showed that the size of the
Ab oligomers is around 100 nm. We then compared the sizes of
the Ab oligomers with and without Cu(II)/Vc treatment, and
found that the size of the treated group was signicantly smaller
than that of the control group (ESI Fig. 8†), indicating that
Cu(II)/Vc is able to degrade the Ab oligomers. However, in this
report we did not intend to compare the degradation speeds of
diﬀerent Ab species.
13. Proliferation studies with neuronal cells
To investigate whether the combination of Cu(II) and Vc can
reduce the neurotoxicity of Abs, we conducted a proliferation
assay with SH-SY5Y neuronal cells treated with (1) Ab42 (20 mM),
(2) Ab42 and Vc (1 : 10), (3) Ab42 and Cu(II) (1 : 1), and (4) Ab42,
Cu(II) and Vc (1 : 1 : 10) for 4 hours and 24 hours. Our data
indicted that Ab42 could indeed apparently reduce the cell
survival rate while Vc alone could not rescue the neurotoxicity of
Ab42. Among the treatments, the lowest cell survival rate (64%)
was in the presence of Ab42 and Cu(II), which could be partially
reversed with the addition of a large excess of Vc (80%) (ESI
Fig. 9†).
14. Cu(II)/Vc combination rescues the Ab impaired synaptic
transmission (fEPSP) in the hippocampus
In AD, dementia severity correlates strongly with decreased
synapse density in the hippocampus and cortex. To characterize
the detrimental eﬀects of Abs in synaptic transmission in the
hippocampal CA1 area, we stimulated the Schaﬀer collateral
pathway once every 15 s and recorded extracellularly from the
stratum radiatum. The fEPSP, which represents the summa-
rized synaptic events from a large population of terminals, was
measured as the negative deection of the voltage trace from
the baseline (Fig. 5a and b). We quantied the maximal fEPSPs
in the control, Ab, and Ab/Cu(II)/Vc groups. Repeated measures
by ANOVA of the three groups showed signicant diﬀerences
among these groups (p < 0.0001). Bonferroni multiple compar-
isons test in diﬀerent group pairs showed that the maximal
fEPSP amplitudes were signicantly smaller in the Ab-treated
slices than in the control groups (control: 1.81  0.18 m; Ab:
0.35  0.05 mV, p < 0.001). Treatment with Cu(II)/Vc prevented
the Ab-induced impairment in synaptic transmission. The
Fig. 4 The degradation of the native Ab40 aggregates induced by Cu(II)/Vc. (a) TEM image of the Ab40 aggregates before degradation (top) and
after degradation (bottom). Right panel: high magniﬁcent image. (b) Thioﬂavin T ﬂuorescence testing with the Ab40 aggregates before
degradation (red) and after degradation (blue). (c) Zoomed in image of the debris of a degraded ﬁbril.
6160 | Chem. Sci., 2017, 8, 6155–6164 This journal is © The Royal Society of Chemistry 2017
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maximal fEPSP amplitude (1.21  0.18 mV) in the Ab/Cu(II)/Vc
group is signicantly larger than that in the Ab group (p < 0.01).
To characterize synaptic plasticity in the C1 area, we deliv-
ered paired pulses (50 ms interval) to the presynaptic terminals,
and recorded the ratio of the fEPSPs (PPF) triggered by the 2nd
pulse to the 1st pulse. Repeated measures by ANOVA of the three
groups showed no diﬀerences among these groups (p ¼ 0.46).
Bonferroni multiple comparisons test in diﬀerent group pairs
showed that the PPF ratios were not diﬀerent among the three
groups (Fig. 5c), indicating that the short-term plasticity was not
impaired.
Discussion
Metal ions play numerous roles in various biological processes.
Their proper balance is crucial for the normal function of
a living being. Copper is an essential metal ion for numerous
metalloproteins, such as ceruloplasmin and cytochrome
oxidase.62 The deciency of copper can lead to various pathol-
ogies such as Menkes disease and Wilson disease.63 On the
other hand, over-accumulation of copper can reportedly
contribute to AD, schizophrenia, and obsessive-compulsive
disorder.51,63 For AD pathology, copper has been considered as
an important trigger in the harmful crosslinking of Abs. In this
report, we demonstrated that copper could play a double-edged
sword role in the fate of Abs. Our results are not contradictory
but complementary to previous studies, and are important for
the complete understanding of the function of copper in AD
pathology.
The degradation of Abs by copper has largely been over-
looked in the past, likely due to the inability of the available Ab
antibodies to recognize small degraded fragments using
western blotting. Harnessing the capability of nano LC-MS/MS,
we clearly showed that Abs could be degraded by copper in the
presence of anti-oxidants. Although the cleavage of Ab model
peptides has been reported, most of the degraded products
identied in our studies diﬀer from previously reported frag-
ments, except for the AEFRHDSGYEV fragment, which shares
the same cleavage site D1 (aspartate) at the N-terminal of the
Ab28 model peptide as identied by Cassagnes et al.64 We also
identied cleavage sites that are diﬀerent from Drew’s report,
which denes E3 as the cleavage site65 using the Ab16 model
peptide. The diﬀerence between our results and those by Cas-
sagnes et al. and Drew et al. could probably be ascribed to the
fact that we used more comprehensive methods for the analysis
of the degraded fragments. In our studies we not only used LC-
MS, but also ran SDS-PAGE to visualize the “visible” FAM-Ab
fragments, which allowed us to ambiguously identify the
degraded products. Moreover, instead of Ab16 and Ab28 that
were used as the model peptides in Cassagnes and Drew’s
reports,64,65 we used the full Ab42 sequence, which more accu-
rately reects the degradation of Ab42. Wu et al. designed
a series of copper complexes that could promote the cleavage of
Abs, and the cleavage sites were similar to our results.66 In
addition, our mechanism studies with the model peptides
support the cleavage sites identied in this report.
While this manuscript was under review, Derrick et al. re-
ported that Ab peptides could be cleaved by complexes of
metal ions and tetra-N-methylated cyclam (TMC) via an
Fig. 5 (a) fEPSP recording of mouse brain slices treated with the vehicle (left), Ab42 (middle), and Ab42/Cu(II)/Vc (right). (b) Quantiﬁcation of the
fEPSP in (a). (c) Quantiﬁcation of the PPF ratio of the vehicle, Ab42, and Ab42/Cu(II)/Vc.
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 6155–6164 | 6161
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intermolecular interaction mechanism.67 Data suggested that
hydrolysis of the amide bond of Abs caused the cleavage, likely
due to the complex [Co(II)(TMC)(H2O)]
2+ leading to a local
increase in the concentration of hydroxide nucleophiles near
the peptide bonds.67 Interestingly, this cleavage mechanism is
quite diﬀerent from our proposed intramolecular metal binding
mechanism. Our data suggested that the cleavage was likely due
to the formation of an Ab-Cu(I)–O2 intermediate and free radi-
cals that consequently cause the cleavage of the nearest amide
bond(s) of the Abs. Although the mechanisms were diﬀerent,
the cleavage eﬃciencies of both mechanisms were comparable
under pH 7.4 conditions (about 60% of Abs are cleaved, calcu-
lated from Fig. 2e in ref. 67).
Iron, copper and zinc are the metal ions that have been
intensively investigated for AD pathology. Interestingly, among
the three metal ions, only copper can induce degradation. It is
not clear why Fe(III) and Fe(II) could not initialize the degrada-
tion. For Fe(III), it is likely due to its weak coordination with Ab
peptides.68,69 Fe(II) could not be reduced by Vc, and this probably
could provide an explanation for our results.68,69 Zn(II) is not
able to induce degradation, which is likely due to its incapa-
bility to participate in redox reactions.
Our results showed that Ab degradation was dependent on
Cu(II) and Vc concentration. With the increase of the Vc
concentration, the degree of degradation was also increased,
and a low concentration of Cu(II) could not signicantly induce
the degradation. We also found that Ab degradation could be
promoted not only by extrinsic anti-oxidants such as Vc, Ve,
resveratrol, and curcumin, but could also be enhanced by
intrinsic anti-oxidants such as dopamine and norepinephrine.
A low dopamine level has been linked to AD.52 We believe that
these results support the benecial eﬀects of a healthy lifestyle
on AD management. A healthy diet can increase the uptake of
vitamins such as Vc, Ve, and reservatrol, and physical exercise
can increase the release of dopamine and norepinephrine.
Our data indicated that copper could play a double-edged
sword role in the fate of Abs. Copper-induced harmful
crosslinking/aggregation and degradation are competitive
paths. If the aggregation path can be suppressed, more Abs will
be degraded. Our data support this hypothesis. We found that
the combination of anti-aggregation agent and Vc could
promote more degradation. Our results suggested that
a formulation of CQ or PBT-2 (ref. 54 and 55) with reservatrol or
other BBB penetrating anti-oxidants could be benecial for AD
treatment.
Our preliminary data are supported by cell proliferation
studies and fEPSP studies with brain slices. Our in vitro Ab
treatment caused signicant impairment in the basic synaptic
transmission, as revealed by the decreased fEPSP magnitude.
Synaptic transmission impairment has been observed in several
AD animal models.70–73 The mechanism is largely unclear, but
could be attributed to the Ab-induced abnormal handling of
calcium inux,74–76 oxidative stress,77 and abnormal activation
of ion channels on the presynaptic cells.73 Interestingly, we did
not observe quantitative changes in the PPF ratio in Ab chal-
lenged slices. It has been reported that in the early stages of AD,
there is no PPF ratio change in AD transgenetic CRND 8
animals.70We speculated that the in vitro Ab challenge implored
in our experiments could only cause mild changes in the elec-
trophysiological proles, including fEPSP, but the short term
plasticity is intact. Our results indicated that copper with a large
excess of Vc could rescue the Ab-induced decit in synaptic
transmission. It would be interesting to test whether the rescue
eﬀects of Cu(II)/Vc could be attributed to the relief of oxidative
stress or prevention of abnormal ion channel functionality.
In conclusion, we would like to reiterate the following points.
First, our results do not contradict previous data, which showed
the harmful eﬀects of copper on AD pathology. Instead, our
studies provide the full picture of copper function in the course
of AD pathology. Second, our data indicated that a large excess
of anti-oxidant is necessary for achieving more degradation.
Third, our studies were conducted in vitro and in mouse brain
slices, and the actual in vivo eﬀect of the combination of copper
and a large excess of anti-oxidant is yet to be conrmed.
Therefore, more studies are warranted for the investigation of
the in vivo benecial eﬀects of the combination.
Materials and methods
Materials, methods, and chemical syntheses are described in
the ESI.† All animal experiments were approved by the Institu-
tional Animal Use and Care Committee at Massachusetts
General Hospital and Loyola University Chicago, and all
experiments were performed in compliance with the relevant
laws and institutional guidelines.
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